Correction to: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes (Cardiovascular Diabetology, (2024), 23, 1, (50), 10.1186/s12933-024-02133-1)
Gamez M., E. Elhegni H., Fawaz S., Ho Ho K., W. Campbell N., A. Copland D., L. Onions K., J. Butler M., J. Wasson E., Crompton M., D. Ramnath R., Qiu Y., Yamaguchi Y., P. Arkill K., O. Bates D., E. Turnbull J., V. Zubkova O., I. Welsh G., Atan D., C. Satchell S., R. Foster R.
Following publication of the original article [1], the author noticed the error in Discussion section. In the last paragraph under Discussion section, the sentence “The heterogenous nature of oligo-/polysaccharide derivatives such as PG545 also results in batch variations, further complicating FDA approval” is incorrect. In this text, PG545 should be replaced with SST0001 and should read “The heterogenous nature of oligo-/polysaccharide derivatives such as SST0001 also results in batch variations, further complicating FDA approval”.